MESTINON Drug Patent Profile
✉ Email this page to a colleague
When do Mestinon patents expire, and what generic alternatives are available?
Mestinon is a drug marketed by Bausch and is included in four NDAs.
The generic ingredient in MESTINON is pyridostigmine bromide. There are eleven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the pyridostigmine bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mestinon
A generic version of MESTINON was approved as pyridostigmine bromide by IMPAX LABS on April 24th, 2003.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MESTINON?
- What are the global sales for MESTINON?
- What is Average Wholesale Price for MESTINON?
Summary for MESTINON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 125 |
| Clinical Trials: | 21 |
| Patent Applications: | 1,329 |
| Drug Prices: | Drug price information for MESTINON |
| What excipients (inactive ingredients) are in MESTINON? | MESTINON excipients list |
| DailyMed Link: | MESTINON at DailyMed |
Recent Clinical Trials for MESTINON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Open Medicine Foundation | PHASE2 |
| Brigham and Women's Hospital | PHASE2 |
| Eastern Virginia Medical School | Phase 4 |
Pharmacology for MESTINON
| Drug Class | Cholinesterase Inhibitor |
| Mechanism of Action | Cholinesterase Inhibitors |
US Patents and Regulatory Information for MESTINON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | MESTINON | pyridostigmine bromide | INJECTABLE;INJECTION | 009830-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Bausch | MESTINON | pyridostigmine bromide | TABLET;ORAL | 009829-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Bausch | MESTINON | pyridostigmine bromide | SYRUP;ORAL | 015193-001 | Approved Prior to Jan 1, 1982 | AA | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Bausch | MESTINON | pyridostigmine bromide | TABLET, EXTENDED RELEASE;ORAL | 011665-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
